<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688476</url>
  </required_header>
  <id_info>
    <org_study_id>2007882387</org_study_id>
    <secondary_id>UG1 242596</secondary_id>
    <nct_id>NCT04688476</nct_id>
  </id_info>
  <brief_title>An Extended Follow-Up Study of the HPV Vaccine Delayed Booster Trial</brief_title>
  <official_title>An Extended Follow-Up Study of the HPV Vaccine Delayed Booster Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an extended follow-up study to follow-up study participants who received 1 booster&#xD;
      dose of Gardasil 9 in the &quot;HPV vaccine delayed booster trial.&quot; This was a prospective,&#xD;
      single-arm, open-label, non-randomized, phase IIa trial among 9-11 year-old girls and boys to&#xD;
      determine the immunogenicity after a single dose of the nonavalent HPV vaccine (Gardasil 9)&#xD;
      over 24 months, with a delayed booster dose at 24 months and an optional booster at 30 months&#xD;
      after the first dose. Participants provided blood specimens at 6, 12, 18, 24, and 30 months&#xD;
      after the first dose. Serologic geometric mean titers (GMT) of the nine vaccine types (HPV&#xD;
      16/18/ 6/11/31/33/45/52/58) were measured at each time point. One hundred and thirty-three&#xD;
      (133) participants received one booster dose at month 24 and elected not to receive the&#xD;
      second booster at month 30.&#xD;
&#xD;
      For this follow-up study, we anticipate that we will be able to accrue 120 participants from&#xD;
      the original study who received just one booster dose. Participants who received one booster&#xD;
      dose of Gardasil 9 will be contacted to return to the clinic to provide blood specimens at 48&#xD;
      (±3), 60 (±3), and 72 (±3) months after the priming dose. Serologic geometric mean titers&#xD;
      (GMT) of the nine vaccine types (HPV 16/18/ 6/11/31/33/45/52/58) will be measured at each&#xD;
      time point.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2020</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The differences in geometric mean titer (GMT) of HPV 16 and HPV18 between 30 vs. 48, 48 vs. 60, and 60 vs. 72 months after the priming dose of Gardasil</measure>
    <time_frame>72 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The differences in geometric mean titer of other HPV types (HPV6/11/31/33/45/52/58) between 30 vs. 48, 48 vs. 60, and 60 vs. 72 months after the priming dose of Gardasil 9</measure>
    <time_frame>72 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>HPV-associated Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum will be collected at each visit for Serologic geometric mean titers (GMT) of the&#xD;
      nine vaccine types (HPV 16/18/ 6/11/31/33/45/52/58).&#xD;
&#xD;
      Urine will be collected at each visit to explore the potential of assessing HPV DNA and&#xD;
      antibodies in the urine.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population is restricted to study participants who received one booster dose of&#xD;
        Gardasil 9 at month 24 and elected not to receive the second booster at month 30 in the&#xD;
        original &quot;HPV vaccine delayed booster trial&quot;.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study participants who received one booster dose of Gardasil 9 at month 24 and elected&#xD;
             not to receive the second booster at month 30 in the original &quot;HPV vaccine delayed&#xD;
             booster trial&quot;&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
             by the legal representative(s) of the participant.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written assent document by the&#xD;
             participant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Has received any HPV vaccine dose from an external source at any point during or after&#xD;
        participation in the HPV vaccine delayed booster trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sherry Chow, PhD</last_name>
    <phone>520-626-3358</phone>
    <email>schow@arizona.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Barbara Moscicki, MD</last_name>
      <phone>310-825-5995</phone>
      <email>AMoscicki@mednet.ucla.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Sherry Chow</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

